Login to Your Account

Sofinnova Double Dealing

Clovis’ $200M EOS Buyout Gets Phase II Breast Cancer Prospect

By Randy Osborne and Cormac Sheridan
Staff Writers

Wednesday, November 20, 2013
“It’s nice to make money with people you like,” said Antoine Papiernik, managing partner at Sofinnova Partners, about the $200 million-up-front deal engineered between Clovis Oncology Inc. and Ethical Oncology Science SpA (EOS).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription